Biotech
Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
Read
Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST
70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!
Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?
Read
Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST
BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave
The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.
Read
Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST
Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments
Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.
Read
Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST
Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa
The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!
Read
Commented by Armin Schulz on July 9th, 2024 | 07:07 CEST
Varta, Cardiol Therapeutics, Evotec - ATTENTION: Something is happening here!
The stock markets are currently seeing increased activity in Varta, Cardiol Therapeutics, and Evotec. Investors should take advantage of the resulting opportunities. Increased volatility and trading volumes can offer attractive short-term gains, while improved liquidity facilitates entry and exit. Additional information flows and momentum effects enhance the dynamics of these stocks, although they also carry increased risks. Sound analysis and prudent risk management are, therefore, essential. We take a closer look at what is currently happening with these three stocks.
Read
Commented by Juliane Zielonka on July 5th, 2024 | 07:35 CEST
Vidac Pharma, BioNTech, GSK: Pioneers in medical progress - Who will win the race?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now?
Read
Commented by Fabian Lorenz on July 4th, 2024 | 07:05 CEST
Takeover battle, boom, and price surge: Evotec, Siemens Energy, Royal Helium in focus
Is Evotec heading for a takeover battle? The share price crash has likely attracted private equity. Now, the biotech company is said to have hired an investment bank for defence plans. An order from the US Department of Defense comes at the right time. Helium is also likely to gain importance in the US. The noble gas is indispensable for quantum computers, rockets, and other high-tech applications. In Canada, Royal Helium is currently making the transition from explorer to producer. The share is ripe for a price surge. Siemens Energy's share price currently only knows the way up. And according to analysts, a further 50% is possible.
Read
Commented by André Will-Laudien on July 1st, 2024 | 07:00 CEST
Attention: Biotech stocks! Evotec, Bayer, and BioNTech in the emergency room, but Cardiol Therapeutics shows strength!
Anyone looking at the buying frenzy on the NASDAQ is overlooking the fact that the US has long been in the emergency room. With the candidates currently up for election, it is unlikely that the most pressing issues of the day will be dealt with. One has difficulty using the right words in front of the camera, while the other ignores facts and slips into his own world. This election could be disastrous for the world's largest economy, but the financial markets are currently uninterested. Investors should, therefore, continue to separate the wheat from the chaff and act prudently. After the big AI and high-tech wave, biotechs are expected to make a comeback, as US interest rates will drop closer to the election. We present a solid selection for risk-conscious investors.
Read
Commented by Armin Schulz on June 25th, 2024 | 08:45 CEST
Evotec, Royal Helium, Nel ASA - Turnaround candidates under review
With the recent rise in shares in Power Nickel, following a bonanza find in its exploration work, the topic of "turnaround candidates on the stock market" is once again coming to the fore. Such companies, which get back on track after significant price falls, offer investors enormous profit potential. The recovery after a deep crisis can represent a second chance for investors but requires a keen sense of market analysis and timing. The success of the investment depends largely on the right selection and timing of entry. We take a look at three candidates.
Read